Robin Respaut
Healthcare and Financial Journalist at Reuters News Agency
Healthcare, financial, data journalist for Reuters. [email protected]
Articles
-
3 days ago |
timeslive.co.za | Chad Terhune |Robin Respaut
04 June 2025 - 11:07 Just R20 for the first month. Support independent journalism by subscribing to our digital news package. The average rate of teens beginning treatment with the highly effective Novo Nordisk drug Wegovy grew 50% last year to 14.8 prescriptions per 100,000 adolescents, according to an analysis by health data firm Truveta. File photo.
-
3 days ago |
jp.reuters.com | Chad Terhune |Robin Respaut
米国でデンマーク製薬大手ノボノルディスクの肥満症治療薬「ウゴービ」を使用する１０代の若者が増加していることが、ヘルスケア情報会社トゥルベタの調査で分かった。写真はペンシルバニア州で２０２３年１１月に撮影（２０２５年 ロイター／Hannah Beier） [ロサンゼルス ３日 ロイター] - 米国でデンマーク製薬大手ノボノルディスク(NOVOb.CO), opens new tabの肥満症治療薬「ウゴービ」を使用する１０代の若者が増加していることが、ヘルスケア情報会社トゥルベタの調査で分かった。調査データをロイターが入手した。若者を対象とした同薬の使用に自信を持つ家族と医師が増えていることが背景にある。 データによると、ウゴービによる治療を始めた１０代の若者の平均処方率は昨年は１０万人当たり１４．８件と前年の同９．９件から５０％上昇した。今年１─３月の平均処方率は同１７．３件でさらに上がっている。 それでもウゴービの処方を受けている若者は、１０万人当たり２万３０００人と推定される肥満症を患う１０代の若者全体のごく一部に過ぎず、成人に比べると処方のペースははるかに遅い。...
-
4 days ago |
dagenspharma.dk | Chad Terhune |Robin Respaut
Wegovy prescriptions for teens remain a small fraction of those with obesityInsurance hurdles limit use among doctors treating adolescentsExperts emphasize need for monitoring, lifestyle changes alongside GLP-1 medicationsLOS ANGELES, June 3 (Reuters) - American teens are increasingly turning to the weight-loss drug Wegovy as more families and their doctors gain confidence in its use for young people with obesity, new data shared with Reuters shows.
-
4 days ago |
reuters.com | Chad Terhune |Robin Respaut
Wegovy presentation is displayed in New Columbia, Pennsylvania, U.S., November 13, 2023.
-
4 days ago |
today.westlaw.com | Robin Respaut |Chad Terhune |Bill Berkrot
LOS ANGELES (Reuters) -American teens are increasingly turning to the weight-loss drug Wegovy as more families and their doctors gain confidence in its use for young people with obesity, new data shared with Reuters shows.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 2K
- Tweets
- 2K
- DMs Open
- Yes
Our latest story examines new data showing the rise of adolescents taking Wegovy, GLP1s, for weight-loss. With @chadterhune https://t.co/K8UY8Q0hHy
RT @chadterhune: Exclusive: US families begin to embrace weight-loss drugs for their children, data show. My latest w/ @RobinRespaut #obesi…
RT @Reuters: As sales soar for Wegovy and Ozempic, there’s growing debate on how widely these powerful and expensive weight-loss medication…